ES2177665T3 - Inhibidores de proteina quinasa para el tratamiento de trastornos neurologicos. - Google Patents
Inhibidores de proteina quinasa para el tratamiento de trastornos neurologicos.Info
- Publication number
- ES2177665T3 ES2177665T3 ES95937391T ES95937391T ES2177665T3 ES 2177665 T3 ES2177665 T3 ES 2177665T3 ES 95937391 T ES95937391 T ES 95937391T ES 95937391 T ES95937391 T ES 95937391T ES 2177665 T3 ES2177665 T3 ES 2177665T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- derivatives
- treatment
- ästauü
- neurological disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- -1 hydrocarbylene radical Chemical class 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA INVENCION PREPARA NUEVOS DERIVADOS DE K-252A P.EJ. (II-4) ASI COMO NUEVOS DERIVADOS BIS-N-SUSTITUIDOS DE ESTAUROSPORINA, DE FORMULA (I). LA INVENCION PRESENTA ASIMISMO, UN METODO DE TRATAMIENTO DE CELULAS NEURONALES ENFERMAS, QUE IMPLICA LA ADMINISTRACION, BIEN DE LOS NUEVOS DERIVADOS DE ESTAUSPORINA, O DE DERIVADOS FUNCIONALES ESPECIFICOS DE K-252A. EN LA FORMULA (I): [STAU]-N(CH{SUB,3})-W-N(CH{SUB,3})-[STAU], [STAU] REPRESENTA UN RESIDUO DE FORMULA (A), Y W REPRESENTA UN RADICAL DE FORMULA: -C(=Y)-NH-W''-NH-C(=Y)-, DONDE W'' ES UN RADICAL HIDROCARBILO DE 2-20 ATOMOS DE CARBONO, E Y ES O O S. EN LA FORMULA (II-4), R{SUP,1}, R{SUP,2}, Z{SUP,1}, Y Z{SUP,2}, SON CADA UNO H; X ES CH{SUB,2}OH; Y R ES OCH{SUB,3}.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/329,540 US5621100A (en) | 1992-07-24 | 1994-10-26 | K-252a derivatives for treatment of neurological disorders |
US08/456,642 US5756494A (en) | 1992-07-24 | 1995-06-02 | Protein kinase inhibitors for treatment of neurological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2177665T3 true ES2177665T3 (es) | 2002-12-16 |
Family
ID=26986843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95937391T Expired - Lifetime ES2177665T3 (es) | 1994-10-26 | 1995-10-04 | Inhibidores de proteina quinasa para el tratamiento de trastornos neurologicos. |
Country Status (12)
Country | Link |
---|---|
US (2) | US5756494A (es) |
EP (2) | EP1125938A1 (es) |
JP (3) | JP3832512B2 (es) |
AT (1) | ATE218571T1 (es) |
AU (1) | AU704314B2 (es) |
BR (1) | BR9509480B1 (es) |
CA (1) | CA2203767A1 (es) |
DE (1) | DE69526956T2 (es) |
ES (1) | ES2177665T3 (es) |
HK (1) | HK1041481A1 (es) |
NZ (1) | NZ295871A (es) |
WO (1) | WO1996013506A1 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811992B1 (en) | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
US6127401A (en) * | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
US6200968B1 (en) * | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
DK1105728T3 (da) * | 1998-08-26 | 2005-08-08 | Cephalon Inc | Modulering af multiple lineage kinase-proteiner |
DE69936059T2 (de) * | 1998-09-25 | 2008-01-24 | Cephalon, Inc. | Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen |
MXPA02000330A (es) | 1999-07-09 | 2004-05-21 | Johnson & Johnson | Pirrolidinas y piperidinas neurotroficas y composiciones y metodos relacionados. |
WO2001004090A2 (en) | 1999-07-09 | 2001-01-18 | Ortho-Mcneil Pharmaceutical, Inc. | Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods |
GB9924962D0 (en) * | 1999-10-21 | 1999-12-22 | Mrc Collaborative Centre | Allosteric sites on muscarinic receptors |
US7129250B2 (en) * | 2000-05-19 | 2006-10-31 | Aegera Therapeutics Inc. | Neuroprotective and anti-proliferative compounds |
CA2308994A1 (en) * | 2000-05-19 | 2001-11-19 | Aegera Therapeutics Inc. | Neuroprotective compounds |
WO2002014536A2 (en) * | 2000-08-11 | 2002-02-21 | Cephalon, Inc. | Odulating multiple lineage kinase proteins |
DE60225271T2 (de) * | 2001-05-09 | 2009-03-05 | Discoverx, Inc., Fremont | Screening auf enzyminhibitoren |
US7018999B2 (en) * | 2001-05-16 | 2006-03-28 | Cephalon, Inc. | Methods for the treatment and prevention of pain |
WO2006002422A2 (en) | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Compounds for immunopotentiation |
MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
US8009751B2 (en) | 2005-10-28 | 2011-08-30 | Sharp Kabushiki Kaisha | Transmitter, communication system and transmission method |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
TW200808739A (en) | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
US20080021013A1 (en) * | 2006-07-21 | 2008-01-24 | Cephalon, Inc. | JAK inhibitors for treatment of myeloproliferative disorders |
US8940771B2 (en) | 2007-12-20 | 2015-01-27 | Novartis Ag | Organic compounds |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
UY33883A (es) | 2011-01-31 | 2012-08-31 | Novartis Ag | Novedosos derivados heterocíclicos |
BR112014009890A2 (pt) | 2011-10-28 | 2020-10-27 | Novartis Ag | derivados de purina e seu uso no tratamento de doença |
RU2630975C2 (ru) | 2012-05-16 | 2017-09-15 | Новартис Аг | Режим дозирования pi-3 киназы |
DK3076969T3 (da) | 2013-12-06 | 2021-11-22 | Novartis Ag | Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer |
AU2016347881A1 (en) | 2015-11-02 | 2018-05-10 | Novartis Ag | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
KR20210135223A (ko) | 2019-03-05 | 2021-11-12 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 펜타시클릭 화합물의 염 및 이의 결정 |
EP3936190A4 (en) | 2019-03-05 | 2022-11-16 | Eisai R&D Management Co., Ltd. | PENTACYCLIC HETEROCYCLIC COMPOUND |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554402A (en) * | 1983-12-23 | 1985-11-19 | Aluminum Company Of America | Vibration damper for overhead conductor |
JPS62120388A (ja) * | 1985-11-19 | 1987-06-01 | Meiji Seika Kaisha Ltd | Sf−2370物質ハロゲン化誘導体とその製造法 |
JPS62155285A (ja) * | 1985-12-27 | 1987-07-10 | Kyowa Hakko Kogyo Co Ltd | 生理活性物質k−252の誘導体 |
JPS62155284A (ja) * | 1985-12-27 | 1987-07-10 | Kyowa Hakko Kogyo Co Ltd | 生理活性物質k−252の誘導体 |
JPS62220196A (ja) * | 1986-03-20 | 1987-09-28 | Kyowa Hakko Kogyo Co Ltd | 新規物質ucn―01 |
US4816450A (en) * | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
JPH0826036B2 (ja) * | 1987-01-22 | 1996-03-13 | 協和醗酵工業株式会社 | 生理活性物質k−252の誘導体 |
JPH0826037B2 (ja) * | 1987-01-22 | 1996-03-13 | 協和醗酵工業株式会社 | 生理活性物質k−252の誘導体 |
US4735939A (en) * | 1987-02-27 | 1988-04-05 | The Dow Chemical Company | Insecticidal activity of staurosporine |
DE3752123T2 (de) * | 1987-03-09 | 1998-05-14 | Kyowa Hakko Kogyo Kk | Derivate des physiologisch aktiven mittels k-252 |
IL86632A0 (en) * | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
US5093330A (en) * | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
JPH07113027B2 (ja) * | 1987-12-24 | 1995-12-06 | 協和醗酵工業株式会社 | K−252誘導体 |
EP0383919A4 (en) * | 1988-02-04 | 1992-08-05 | Kyowa Hakko Kogyo Co., Ltd. | Staurosporin derivatives |
DE3835842A1 (de) * | 1988-10-21 | 1990-04-26 | Goedecke Ag | Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel |
DE3924538A1 (de) * | 1989-07-25 | 1991-01-31 | Goedecke Ag | Indolocarbazol und dessen verwendung |
AU7035991A (en) * | 1989-12-14 | 1991-07-18 | Schering Corporation | Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856 |
JPH0586068A (ja) * | 1991-03-04 | 1993-04-06 | Rikagaku Kenkyusho | 新規抗生物質rk−1409、その製造法並びに抗腫瘍剤及び抗炎症剤 |
WO1993008809A1 (en) * | 1991-11-08 | 1993-05-13 | The University Of Southern California | Compositions containing k-252 compounds for potentiation of neurotrophin activity |
US6271242B1 (en) * | 1992-02-10 | 2001-08-07 | Bristol-Myers Squibb Co. | Method for treating cancer using a tyrosine protein kinase inhibitor |
JPH05247055A (ja) * | 1992-03-03 | 1993-09-24 | Meiji Seika Kaisha Ltd | スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤 |
EP0575955B1 (en) * | 1992-06-22 | 1999-09-15 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing staurosporine derivatives |
JPH0673063A (ja) * | 1992-06-22 | 1994-03-15 | Kyowa Hakko Kogyo Co Ltd | Ucn−01誘導体 |
US5461146A (en) * | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
DE69409641T2 (de) * | 1993-05-28 | 1998-11-26 | Cephalon Inc | Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen |
JPH08511785A (ja) * | 1993-06-17 | 1996-12-10 | チバ−ガイギー アクチェンゲゼルシャフト | プロテインキナーゼc阻害剤として有用なインドロカルバゾール |
-
1995
- 1995-06-02 US US08/456,642 patent/US5756494A/en not_active Expired - Lifetime
- 1995-10-04 AU AU39516/95A patent/AU704314B2/en not_active Expired
- 1995-10-04 EP EP01110483A patent/EP1125938A1/en not_active Withdrawn
- 1995-10-04 NZ NZ295871A patent/NZ295871A/en not_active IP Right Cessation
- 1995-10-04 EP EP95937391A patent/EP0788501B1/en not_active Expired - Lifetime
- 1995-10-04 WO PCT/US1995/012965 patent/WO1996013506A1/en not_active Application Discontinuation
- 1995-10-04 BR BRPI9509480-6A patent/BR9509480B1/pt not_active IP Right Cessation
- 1995-10-04 ES ES95937391T patent/ES2177665T3/es not_active Expired - Lifetime
- 1995-10-04 JP JP51460596A patent/JP3832512B2/ja not_active Expired - Fee Related
- 1995-10-04 AT AT95937391T patent/ATE218571T1/de not_active IP Right Cessation
- 1995-10-04 DE DE69526956T patent/DE69526956T2/de not_active Expired - Lifetime
- 1995-10-04 CA CA002203767A patent/CA2203767A1/en not_active Abandoned
-
1997
- 1997-02-14 US US08/800,383 patent/US5741808A/en not_active Expired - Fee Related
-
2002
- 2002-02-21 HK HK02101296.7A patent/HK1041481A1/zh unknown
-
2005
- 2005-05-24 JP JP2005150815A patent/JP2005314429A/ja not_active Withdrawn
- 2005-12-12 JP JP2005357071A patent/JP2006117690A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2005314429A (ja) | 2005-11-10 |
EP0788501B1 (en) | 2002-06-05 |
JP3832512B2 (ja) | 2006-10-11 |
BR9509480B1 (pt) | 2009-01-13 |
CA2203767A1 (en) | 1996-05-09 |
NZ295871A (en) | 2001-09-28 |
DE69526956D1 (de) | 2002-07-11 |
MX9703039A (es) | 1998-12-31 |
US5756494A (en) | 1998-05-26 |
EP0788501A1 (en) | 1997-08-13 |
BR9509480A (pt) | 1997-09-30 |
WO1996013506A1 (en) | 1996-05-09 |
AU704314B2 (en) | 1999-04-22 |
US5741808A (en) | 1998-04-21 |
AU3951695A (en) | 1996-05-23 |
JP2006117690A (ja) | 2006-05-11 |
JPH10510514A (ja) | 1998-10-13 |
ATE218571T1 (de) | 2002-06-15 |
DE69526956T2 (de) | 2002-12-19 |
HK1041481A1 (zh) | 2002-07-12 |
EP1125938A1 (en) | 2001-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2177665T3 (es) | Inhibidores de proteina quinasa para el tratamiento de trastornos neurologicos. | |
DK0651754T3 (da) | K-252a-derivater | |
DE69625518D1 (de) | Wirkstoff zur behandlung neurodegenerativer störungen | |
FI853625L (fi) | Tetralinderivat, deras framstaellning och anvaendning. | |
CO4340622A1 (es) | Nuevos macrociclos bis-indolil maleimida | |
AU3142597A (en) | Dha-pharmaceutical agent conjugates | |
ES2181853T3 (es) | Tratamiento del tinnitus empleando agentes neuroprotectores. | |
NO944339D0 (no) | Melatoninderivater for anvendelse ved behandling av sövnforstyrrelser | |
ATE141796T1 (de) | 2',5'-oligoadenylat-derivate zur verwendung als heilmittel | |
FI880385A0 (fi) | Substituerade 3-fenyl-7h-tiazolo /3,2-b//1,2,4/-triazin-7-oner, foerfaranden foer deras framstaellning, dessa innehaollande laekemedel och deras anvaendning, samt naogra vid framstaellningen av naemnda foereningar bildade mellanprodukter. |